Quantcast
Last updated on April 16, 2014 at 4:43 EDT

Latest Fluticasone/salmeterol Stories

2013-05-06 08:30:49

NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs. (Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-a )(Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-b ) The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's leading acid blocker,...

2012-06-18 02:25:49

ALBANY, New York, June 18, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 - 2017 [http://www.transparencymarketresearch.com/asthma-and-copd-market.html ]", the global asthma and COPD market was worth USD 25,102.3 million in 2010, which is expected to reach USD 26,965.5 million...

2012-05-31 02:26:36

NEW YORK, May 31, 2012 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials, updates, and intelligence recently reviewed the results presented at the American Thoracic Society (ATS) conference held May 18-23, 2012 in San Francisco, CA. The strong competition to launch the next fixed dose combination (FDC) blockbuster for chronic obstructive pulmonary disease (COPD) was of particular interest to reviewer Jennifer Stacey, Citeline's Analyst in...

2012-05-09 06:26:38

Allergy & Asthma Network Mothers of Asthmatics (AANMA) Names 10 Winners at Allergy & Asthma Day Capitol Hill 2012 WASHINGTON, May 9, 2012 /PRNewswire-USNewswire/ -- Allergy & Asthma Network Mothers of Asthmatics (AANMA), a leading national nonprofit patient-education organization, announces the Top Ten Innovations in Technology Awards - products and services that have meaningfully improved quality of life for people with allergies, asthma and related conditions. "When you...

2012-04-01 22:20:46

TOKYO, April 2, 2012 /PRNewswire/ -- Efficacy, safety and exercise endurance primary endpoints all met Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), confirms the information released today by Novartis that the first three QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints. The SHINE, BRIGHT and ENLIGHTEN studies, which are part of the IGNITE program demonstrate the potential of...

2011-11-09 06:30:00

PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair® Diskus and Seretide® Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform. Advair® Diskus and Seretide® Diskus are inhaled...

2011-10-28 13:00:00

REDWOOD CITY, Calif., Oct. 28, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. presented data elucidating the robust aerosol performance and physicochemical foundations of the Company's cosuspension technology which uses spray-dried, low-density porous particles to deliver drug microcrystals via pressurized metered dose inhalers (MDIs). Two posters were presented this week at the 25th American Association of Pharmaceutical Scientists annual meeting in Washington DC. "These results...

2011-10-28 06:30:00

CAPE CORAL, Fla., Oct. 28, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures (MILV.pk), has entered into the $8.4 billion market chronic obstructive pulmonary disease market (COPD) with the completed acquisition of a ground breaking Breathing Formula. This all natural, non-synthetic, medicine was developed for the treatment of COPD, the two most common forms of which are Emphysema and Chronic Bronchitis. We believe that there is no other product...

2010-12-06 10:00:00

BURLINGTON, Mass., Dec. 6, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim/Pfizer's Spiriva will most likely strengthen its position among the sales leaders for the treatment of chronic obstructive pulmonary disease (COPD) through greater use in the primary care setting. GlaxoSmithKline's Advair and Spiriva are the sales leaders in the COPD market, and hold similar...

2010-12-01 00:33:35

Office-based primary care doctors rank GSK's sales force number one, a jump from third in 2009. Pfizer finished second and Merck placed third this year. Plymouth Meeting, PA (Vocus) November 30, 2010 According to SDI's 2010 Ranking Tables Study, office-based primary care physicians "“ general practitioners, family medicine physicians, and doctors of osteopathy "“ rank GlaxoSmithKline's sales force number one, a jump from third in 2009. Pfizer finished second and Merck placed...